Basic Study
Copyright ©The Author(s) 2016.
World J Hepatol. Dec 28, 2016; 8(36): 1610-1616
Published online Dec 28, 2016. doi: 10.4254/wjh.v8.i36.1610
Table 1 Comparison of the characteristics of the controls and study patients with biopsy proven
Biopsy-proven ALDBiopsy-proven NAFLDClinically diagnosed NAFLDControlsP value
(n = 14)(n = 9)(n = 16)(n = 10)Biopsy-proven ALD vs NAFLD
Age (yr)53 (45-60)54 (49-66)49 (43-54)51 (39-60)NS
Gender (male:female)11:36:316:010:0NS
AST (U/L)74 (41-105)45 (38-95)32 (24-42)19 (15-21)NS
ALT (U/L)19 (13-22)35 (27-67)48 (35-74.5)18 (14-20)0.0166
Albumin (g/dL)4.1 (3.2-4.4)4.6 (4.1-4.7)4.4 (4.3-4.6)4.6 (4.3-4.8)NS
Total bilirubin (mg/dL)1 (0.6-3.1)0.7 (0.6-0.8)0.8 (0.6-0.9)0.9 (0.6-1.2)NS
Triglyceride (mg/dL)186 (99-284)184 (101-298)187 (102-212)130 (111-139)NS
HDL-cholesterol (mg/dL)40 (30-56)43 (29-52)42 (39-54)50 (42-56)NS
LDL -cholesterol (mg/dL)75 (43-105)116 (97-153)122 (98-157)113 (101-136)0.0181
GGT (U/L)368 (296-421)94 (62-170)74 (57-112)24 (19-42)0.0018
b/t-GGT ratio0.1 (0.07-0.13)0.16 (0.13-0.26)0.18 (0.14-0.24)0.12 (0.08-0.15)NS
m/t-GGT ratio0.04 (0.02-0.05)0.04 (0.02-0.05)0.04 (0.03-0.05)0.02 (0.02-0.03)NS
s/t-GGT ratio0.78 (0.65-0.80)0.55 (0.49-0.64)0.54 (0.49-0.60)0.4 (0.31-0.44)0.0158
f/t-GGT ratio0.12 (0.08-0.15)0.18 (0.15-0.26)0.23 (0.15-0.29)0.45 (0.37-0.63)0.0055
b/s-GGT ratio0.14 (0.09-0.20)0.33 (0.21-0.53)0.35 (0.24-0.51)0.29 (0.19-0.52)0.0456
s/f-GGT ratio6.68 (3.67-10.58)3.1 (2.18-4.32)2.09 (1.69-3.98)0.96 (0.48-1.11)0.0086